Ieq Capital LLC bought a new position in IQVIA Holdings Inc. (NYSE:IQV – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 88,387 shares of the medical research company’s stock, valued at approximately $17,078,000.
Other institutional investors have also recently made changes to their positions in the company. Financial Freedom LLC purchased a new position in IQVIA in the 1st quarter worth approximately $25,000. Ascentis Independent Advisors purchased a new stake in IQVIA during the 1st quarter valued at $25,000. International Assets Investment Management LLC bought a new stake in shares of IQVIA in the 4th quarter worth $27,000. Gilpin Wealth Management LLC bought a new stake in shares of IQVIA in the 4th quarter worth $27,000. Finally, CrossGen Wealth LLC purchased a new position in shares of IQVIA in the fourth quarter worth $28,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.
IQVIA Stock Performance
Shares of IQV opened at $260.17 on Friday. The firm has a market capitalization of $42.82 billion, a P/E ratio of 32.28, a PEG ratio of 2.21 and a beta of 1.18. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $260.40. The business has a fifty day moving average of $213.32 and a 200 day moving average of $187.52.
IQVIA announced that its Board of Directors has initiated a share repurchase plan on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.
Wall Street Analysts Forecast Growth
Several equities research analysts recently commented on IQV shares. TD Cowen increased their price objective on IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Morgan Stanley reissued an “equal weight” rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Barclays reaffirmed an “overweight” rating on shares of IQVIA in a report on Tuesday, July 28th. Royal Bank Of Canada lifted their price target on shares of IQVIA from $221.00 to $247.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. Finally, HSBC reissued a “buy” rating and set a $240.00 price objective on shares of IQVIA in a report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $241.88.
Read Our Latest Analysis on IQV
Insider Buying and Selling at IQVIA
In other news, insider W Richard Staub sold 5,500 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the transaction, the insider owned 13,312 shares in the company, valued at $3,097,436.16. This represents a 29.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Eric Sherbet sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the transaction, the insider directly owned 20,999 shares in the company, valued at approximately $5,232,110.84. The trade was a 19.23% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 12,913 shares of company stock worth $3,098,793 over the last 90 days. 1.70% of the stock is owned by company insiders.
IQVIA Company Profile
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
Read More
- Five stocks we like better than IQVIA
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
